Anyone, any disease, any target. About 20 years ago, Prof Frank Gunn-Moore, University of St Andrews discovered a protein, which he suspected was involved in the deterioration of the brain that causes dementia.
Thanks to funding from SULSA, Dr Laura Aitken, postdoc in his group, could develop an HTS-compatible assay which was successfully submitted to ELF. In a recent interview, Laura Aitken and Frank Gunn-Moore, explained how academic groups can accelerate their research in collaboration with the European Lead Factory.
Watch the video here or read Laura Aitken's testimonial.
© European Lead Factory and its partners.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.
This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).